NSSC vs SNDX Comparison

NAPCO Security Technologies Inc develops, manufactures, and distributes security products, including access control systems, door security products, intrusion and fire alarm systems, alarm communication services, and video surveillance products for commercial and residential use. The Company also provides wireless communication services for intrusion and fire alarm systems. Its products include Intrusion and Access Alarm Products, Door Locking Devices and Services. The products are used for commercial, residential, institutional, industrial and governmental applications and are sold principally to independent distributors, dealers and installers of security equipment. The Company generates maximum revenue from the United States.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.